The Arnesen Lab is part of a new European Proteomics Infrastructure Consortium

UiB.no: EPIC-XS: Ten Million Euro for Access to European Proteomics Facilities

The discovery of the actin's N-terminal acetyltransferase NAA80

Cytoskeleton commentary: Actin's N‐terminal acetyltransferase uncovered

PNAS commentary: NATure of actin amino-terminal acetylation

NBS Nytt: Actin Acetylation [Norwegian]

UiB.no:  Putting a break on cell movement

 

 

Arnesen receives the ERC Consolidator Grant

UIB.no: ERC consolidator grant to Thomas Arnesen

Forskningsrådet.no: Banebrytende forskning ble belønnet [Norwegian]

Påhøyden.no: Får høythengende EU-midler [Norwegian]

 

Arnesen received funding from the Norwegian Cancer Society

NRK.no: Forsker fikk gave på 4,5 mill [Norwegian]

 

On the discovery of deadly gene defect in NAA10

Påhøyden.no: Deadly gene defect is uncovered

 

 

Arnesen receives the Bergen Research Foundation Starting Grant

Påhøyden.no: To nye rekrutteringsstipend [Norwegian]

 

Could NatA play a role in Huntington’s disease?

Påhøyden.no: Kreftforskere fant info om livsfarlig sykdom [Norwegian]

 

N-terminal acetyltransferases are conserved from yeast to human

Påhøyden.no Nye skritt mot bedre kreftmedisin [Norwegian]

Copyright: European Union

Copyright: European Union

Copyright: PNAS

Copyright: PNAS

LOGO_ERC.jpg
Kreftforeningen_Logo.png
Thomas Arnesen and Johan Lillehaug

Thomas Arnesen and Johan Lillehaug

bfs-weblogo-1.jpg